Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: APP009
MIFTS: 41

Appendix Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Appendix Adenocarcinoma

About this section

MalaCards integrated aliases for Appendix Adenocarcinoma:

Name: Appendix Adenocarcinoma 12 15 17
Mucinous Adenocarcinoma 54 74
Cystadenocarcinoma 54 74
Adenocarcinoma of the Appendix 54
Colonic Type Adenocarcinoma 54
Appendiceal Adenocarcinoma 12
Nonmucinous Adenocarcinoma 54
Adenocarcinoma of Appendix 74

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3608
NCIt 51 C7718
Sources

Summaries for Appendix Adenocarcinoma

About this section
NIH Rare Diseases : 54 Cancer of the appendix is very rare and is typically found incidentally during appendectomies, in about 1% of the cases. According to a report published by the National Cancer Institute, using the Surveillance, Epidemiology, and End Results (SEER) database, appendix cancer account for about 0.4% of gastrointestinal tumors. There are several subytpes. The most common is the carcinoid type (66% of the total), with cyst-adenocarcinoma accounting for 20% and adenocarcinoma accounting for 10%. Then there are the rare forms of cancers which include adenocarcinoid, signet ring, non-Hodgkin�??s lymphoma, ganglioneuroma, and pheochromocytoma. Benign primary tumors are mainly �??mucinous epithelial neoplasms�?�, also called adenomas, cystadenoma, and benign neoplastic mucocele.Adenocarcinoma of the appendix is a epithelial cancer of the appendix. The term 'epithelium' refers to cells that line hollow organs and glands and those that make up the outer surface of the body. Epithelial cells help to protect or enclose organs. Some produce mucus or other secretions. Types of adenocarcinoma of the appendix include mucinous adenocarcinoma, non-mucinous adenocarcinoma, and signet cell carcinoma of the appendix (which is the rarest, involving only 4% of all the subtypes of appendix cancer).

MalaCards based summary : Appendix Adenocarcinoma, also known as mucinous adenocarcinoma, is related to mucinous cystadenocarcinoma and bile duct cystadenocarcinoma. An important gene associated with Appendix Adenocarcinoma is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways is Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Bevacizumab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include appendix, colon and liver.

Disease Ontology : 12 An appendix carcinoma that derives from epithelial cells of glandular origin.

Sources

Related Diseases for Appendix Adenocarcinoma

About this section

Diseases related to Appendix Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 295)
# Related Disease Score Top Affiliating Genes
1 mucinous cystadenocarcinoma 33.9 KRT20 KRT7
2 bile duct cystadenocarcinoma 33.5 KRT20 KRT7
3 mucinous adenocarcinoma 33.4 CDX2 KRT20 KRT7
4 ovarian mucinous adenocarcinoma 33.3 CDX2 KRT20 KRT7
5 pseudomyxoma peritonei 32.0 CDX2 KRT20 KRT7
6 papillary serous adenocarcinoma 31.5 KRT20 KRT7
7 teratoma 30.7 CDX2 KRT7
8 villous adenoma 30.4 CDX2 KRT20
9 krukenberg carcinoma 30.3 KRT20 KRT7
10 cystic teratoma 30.1 CDX2 KRT20 KRT7
11 large cell neuroendocrine carcinoma 30.0 KRT20 KRT7
12 thymus adenocarcinoma 29.9 CDX2 KRT20 KRT7
13 vulva adenocarcinoma 29.9 CDX2 KRT20 KRT7
14 mucinous ovarian cystadenoma 29.8 CDX2 KRT7
15 clear cell adenocarcinoma 29.8 KRT20 KRT7
16 small cell carcinoma 29.8 KRT20 KRT7
17 transverse colon cancer 29.8 KRT20 KRT7
18 adenocarcinoma in situ 29.8 CDX2 KRT20 KRT7
19 cystadenoma 29.7 KRT20 KRT7
20 dermoid cyst 29.7 KRT20 KRT7
21 cholangiocarcinoma 29.6 CDX2 KRT20 KRT7
22 pancreatic ductal carcinoma 29.6 KRT20 KRT7
23 polycystic liver disease 1 with or without kidney cysts 29.6 KRT20 KRT7
24 signet ring cell adenocarcinoma 29.5 CDX2 KRT20 KRT7
25 sweat gland cancer 29.5 KRT20 KRT7
26 intrahepatic cholangiocarcinoma 29.4 CDX2 KRT20 KRT7
27 transitional cell carcinoma 29.4 KRT20 KRT7
28 endocervical adenocarcinoma 29.4 CDX2 KRT20 KRT7
29 cervical adenocarcinoma 29.4 CDX2 KRT20 KRT7
30 horseshoe kidney 29.4 CDX2 KRT20 KRT7
31 intestinal obstruction 29.4 CDX2 KRT20 KRT7
32 colorectal adenocarcinoma 29.4 CDX2 KRT20 KRT7
33 lung cancer susceptibility 3 29.2 CDX2 KRT20 KRT7
34 appendix cancer 28.7 CDX2 KRT20 KRT7 RHCE
35 serous cystadenocarcinoma 12.5
36 papillary cystadenocarcinoma 12.5
37 ovarian mucinous cystadenocarcinoma 12.5
38 pancreatic serous cystadenocarcinoma 12.4
39 villoglandular variant cervical mucinous adenocarcinoma 12.4
40 signet ring cell variant cervical mucinous adenocarcinoma 12.4
41 intestinal variant cervical mucinous adenocarcinoma 12.4
42 colon mucinous adenocarcinoma 12.4
43 endometrial mucinous adenocarcinoma 12.4
44 mucinous adenocarcinoma of ovary 12.3
45 cervical mucinous adenocarcinoma 12.3
46 mucinous adenocarcinoma of the appendix 12.3
47 ovarian serous cystadenocarcinoma 12.3
48 lung mucinous cystadenocarcinoma 12.3
49 ovarian clear cell cystadenocarcinoma 12.3
50 pancreatic cystadenocarcinoma 12.2

Graphical network of the top 20 diseases related to Appendix Adenocarcinoma:



Diseases related to Appendix Adenocarcinoma
Sources

Symptoms & Phenotypes for Appendix Adenocarcinoma

About this section
Sources

Drugs & Therapeutics for Appendix Adenocarcinoma

About this section

Drugs for Appendix Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 6857599 5310940 9887054 43805
4
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
5
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
7
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
8
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
9
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
10
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
11
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
12
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3 112809-51-5 3902
14
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
15
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
16
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177 70789204
17
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
18
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
19
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123948-87-8, 119413-54-6 60700
20
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
21
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
22
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
23
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
24
Gemcitabine Approved Phase 2, Phase 3,Phase 3,Phase 1 95058-81-4 60750
25
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 14219 4091
26
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
27
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
28
Sodium Citrate Approved, Investigational Phase 2, Phase 3 68-04-2
29
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
30
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 7440-70-2 271
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
32
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
33
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
34
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
35 Edrecolomab Experimental, Investigational Phase 3 156586-89-9
36
Camptothecin Experimental Phase 3 7689-03-4
37
SB-649868 Experimental, Investigational Phase 2, Phase 3,Phase 1 110-16-7, 110-17-8 444972
38
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
39 Paclitaxel poliglumex Experimental, Investigational Phase 3,Phase 1 263351-82-2
40 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
41 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
44 Antidotes Phase 3,Phase 2,Phase 1
45 Antimetabolites Phase 3,Phase 2,Phase 1
46 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Early Phase 1
47 Hormones Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Nutrients Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
50 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 216)
# Name Status NCT ID Phase Drugs
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
3 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
4 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
8 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
9 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
10 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
11 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
12 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
13 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
14 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
15 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
16 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
17 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
18 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
19 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
20 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
21 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
22 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
23 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
24 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
25 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
26 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
27 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
28 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
29 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
30 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
31 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
32 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
33 Second Look Laparoscopy in Colorectal Cancer Unknown status NCT01628211 Phase 2 Folinic Acid;5-Fluorouracil;Oxaliplatin;systemic chemotherapy
34 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
35 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
36 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Unknown status NCT02059265 Phase 2 Dasatinib
37 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
38 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
39 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
40 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
41 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
42 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
43 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
44 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
45 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
46 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
47 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
48 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
49 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
50 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel

Search NIH Clinical Center for Appendix Adenocarcinoma

Sources

Genetic Tests for Appendix Adenocarcinoma

About this section
Sources

Anatomical Context for Appendix Adenocarcinoma

About this section

MalaCards organs/tissues related to Appendix Adenocarcinoma:

42
Appendix, Colon, Liver, Breast, Lymph Node, Lung, Bone
Sources

Publications for Appendix Adenocarcinoma

About this section

Articles related to Appendix Adenocarcinoma:

(show top 50) (show all 71)
# Title Authors Year
1
Mucinous adenocarcinoma of the abdomen. ( 30900376 )
2019
2
Calcified mucinous adenocarcinoma of the stomach metastatic to the iris: a case report. ( 30841908 )
2019
3
Malignant melanoma of the esophagus complicated with poorly differentiated mucinous adenocarcinoma of the stomach: A case report. ( 30855489 )
2019
4
Bevacizumab Combined With Oxaliplatin/Capecitabine in Patient With Refractory and Recurrent Mucinous Adenocarcinoma of the Appendix: A Case Report. ( 30792968 )
2019
5
Solitary Nodular Invasive Mucinous Adenocarcinoma of the Lung: Imaging Diagnosis Using the Morphologic-Metabolic Dissociation Sign. ( 30799583 )
2019
6
Clinicopathological characteristics of patients with mucinous adenocarcinoma of the uterine cervix: a retrospective study of 21 cases. ( 30807852 )
2019
7
MRI features of mucinous adenocarcinoma of the prostate: report of four cases. ( 30810795 )
2019
8
Ciliated muconodular papillary tumour of the lung mimicking mucinous adenocarcinoma: a case report and literature review. ( 30713144 )
2019
9
Primary Mucinous Adenocarcinoma of Skin in Axilla: A Case Report and Review of Literature. ( 30745645 )
2019
10
Mucinous adenocarcinoma of the endometrium with metastasis to the clitoral glans after pelvic exenteration for radiation resistant vaginal cuff recurrence. ( 30627614 )
2019
11
A Novel CAMKMT Exon3-ALK Exon20 Fusion Variant was Identified in a Primary Pulmonary Mucinous Adenocarcinoma. ( 30579547 )
2019
12
Mucinous adenocarcinoma of gallbladder: Subcategorisation on fine-needle aspiration cytology. ( 30375181 )
2019
13
Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma. ( 29771808 )
2018
14
Non-human Papillomavirus Cervical Mucinous Adenocarcinoma in a Phenotypic Male with Congenital Adrenal Hyperplasia. ( 30680268 )
2018
15
Invasive Mucinous Adenocarcinoma in Congenital Pulmonary Airway Malformation: A Case Report. ( 30595422 )
2018
16
hCG production by mucinous adenocarcinoma of the ovary in a reproductive aged woman. ( 30533474 )
2018
17
A rare case of incidental mucinous adenocarcinoma with osseous metaplasia associated with cysts of the presacral space. ( 30460902 )
2018
18
Anaplastic Carcinoma Arising From Ovarian Mucinous Adenocarcinoma With Massive Cardiopulmonary Metastasis: An Autopsy Case Report. ( 30393058 )
2018
19
Multicentric Mucinous Adenocarcinoma in the Periorbital Region. ( 30365480 )
2018
20
Intestinal epithelial Notch-1 protects from colorectal mucinous adenocarcinoma. ( 30323897 )
2018
21
Trends of incidence and survival in patients with gastrointestinal mucinous adenocarcinoma. ( 30344730 )
2018
22
Invasive mucinous adenocarcinoma of the lung in a 19-year-old female. ( 30269525 )
2018
23
Incidental discovery of mucinous adenocarcinoma of the prostate following transurethral resection of the prostate: A report of two cases and a literature review. ( 30214732 )
2018
24
Primary mucinous adenocarcinoma of the eyelid: A case report and literature review. ( 30251739 )
2018
25
Colonic adenosquamous carcinoma and mucinous adenocarcinoma with microsatellite instability. ( 30173239 )
2018
26
Favorable response to pemetrexed, cisplatin and bevacizumab in invasive mucinous adenocarcinoma: A case report and literature review. ( 30101020 )
2018
27
Urachal mucinous adenocarcinoma in the pelvic wall mimicking endometriosis. ( 30108674 )
2018
28
Can Quantitative Volumetric Analysis Predict Tumor Recurrence in the Patients with Mucinous Adenocarcinoma of the Lung After Surgical Resection? ( 30064921 )
2018
29
Effect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study. ( 30069357 )
2018
30
Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. ( 29992451 )
2018
31
Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma. ( 29983574 )
2018
32
Mucinous adenocarcinoma of the thymus: report of a case. ( 28474330 )
2018
33
Computerized margin and texture analyses for differentiating bacterial pneumonia and invasive mucinous adenocarcinoma presenting as consolidation. ( 28545080 )
2017
34
Long-tract ileocolic intussusception due to mucinous adenocarcinoma of the ileocecal valve: a case report and literature review. ( 28458844 )
2017
35
Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings. ( 28096683 )
2017
36
Gene signature driving invasive mucinous adenocarcinoma of the lung. ( 28255028 )
2017
37
External Validation of the Simplified Preoperative Assessment for Low-Grade Mucinous Adenocarcinoma of the Appendix. ( 28315061 )
2017
38
The association between small tumor size and poor survival in T4 mucinous adenocarcinoma of colon without distant metastasis. ( 28365951 )
2017
39
Effect of Neoadjuvant Chemoradiotherapy on Locally Advanced Rectal Mucinous Adenocarcinoma: A Propensity Score-Matched Study. ( 28400820 )
2017
40
Serrated adenocarcinoma morphology in colorectal mucinous adenocarcinoma is associated with improved patient survival. ( 28422723 )
2017
41
Invasive mucinous adenocarcinoma of the lung presenting as a large, thin-walled cyst: A case report and literature review. ( 28451428 )
2017
42
Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma. ( 28451462 )
2017
43
Intestinal differentiated mucinous adenocarcinoma of the endometrium with sporadic MSI high status: a case report. ( 28494767 )
2017
44
Primary Villoglandular Mucinous Adenocarcinoma of the Vulva. ( 28503335 )
2017
45
Rectal Mucinous Adenocarcinoma: MR Imaging Assessment of Response to Concurrent Chemotherapy and Radiation Therapy-A Hypothesis-generating Study. ( 28520513 )
2017
46
Cons: the confusing mucinous adenocarcinoma classification. ( 28529906 )
2017
47
Differential diagnosis of a rare papillary tumor and mucinous adenocarcinoma. ( 28554219 )
2017
48
Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers. ( 28577958 )
2017
49
Mucinous Adenocarcinoma of the Appendix: A Case Report. ( 28588185 )
2017
50
Appendix adenocarcinoma in an elderly patient from a nursing home. ( 27436927 )
2016
Sources

Variations for Appendix Adenocarcinoma

About this section

Cosmic variations for Appendix Adenocarcinoma:

9 (show top 50) (show all 362)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6938356 ZFHX3 large intestine,appendix,carcinoma,adenocarcinoma c.3122A>C p.K1041T 16:72950563-72950563 0
2 COSM6933903 XIAP large intestine,appendix,carcinoma,adenocarcinoma c.591A>T p.Q197H 23:123886253-123886253 0
3 COSM6976113 WT1 large intestine,appendix,carcinoma,adenocarcinoma c.463G>A p.D155N 11:32428599-32428599 0
4 COSM44944 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.451C>G p.P151A 17:7675161-7675161 0
5 COSM10704 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.844C>T p.R282W 17:7673776-7673776 0
6 COSM10645 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.527G>T p.C176F 17:7675085-7675085 0
7 COSM10808 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.488A>G p.Y163C 17:7675124-7675124 0
8 COSM11286 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.1015G>T p.E339* 17:7670694-7670694 0
9 COSM10863 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.833C>T p.P278L 17:7673787-7673787 0
10 COSM11073 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.1024C>T p.R342* 17:7670685-7670685 0
11 COSM10659 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.817C>T p.R273C 17:7673803-7673803 0
12 COSM43955 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.514G>A p.V172I 17:7675098-7675098 0
13 COSM10648 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.524G>A p.R175H 17:7675088-7675088 0
14 COSM10662 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.743G>A p.R248Q 17:7674220-7674220 0
15 COSM10794 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.796G>A p.G266R 17:7673824-7673824 0
16 COSM12193 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.668C>T p.P223L 17:7674863-7674863 0
17 COSM44093 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.644G>A p.S215N 17:7674887-7674887 0
18 COSM43872 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.560-1G>C p.? 17:7674972-7674972 0
19 COSM6901 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.559+1G>A p.? 17:7675052-7675052 0
20 COSM44388 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.853G>T p.E285* 17:7673767-7673767 0
21 COSM11183 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.799C>T p.R267W 17:7673821-7673821 0
22 COSM10883 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.731G>A p.G244D 17:7674232-7674232 0
23 COSM6954252 TOP1 large intestine,appendix,carcinoma,adenocarcinoma c.1303A>G p.I435V 20:41101348-41101348 0
24 COSM6938933 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.1069G>T p.G357W 3:30672252-30672252 0
25 COSM2983542 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.1582C>G p.R528G 3:30691477-30691477 0
26 COSM33076 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.1583G>A p.R528H 3:30691478-30691478 0
27 COSM6503127 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.155A>C p.K52T 3:30644807-30644807 0
28 COSM6967188 TCF7L2 large intestine,appendix,carcinoma,adenocarcinoma c.1760C>T p.P587L 10:113165941-113165941 0
29 COSM6083762 STK11 large intestine,appendix,carcinoma,adenocarcinoma c.752G>T p.G251V 19:1221230-1221230 0
30 COSM6932862 STAT3 large intestine,appendix,carcinoma,adenocarcinoma c.365C>T p.A122V 17:42345566-42345566 0
31 COSM6938938 SPOP large intestine,appendix,carcinoma,adenocarcinoma c.413G>A p.R138H 17:49619048-49619048 0
32 COSM4067486 SPOP large intestine,appendix,carcinoma,adenocarcinoma c.295C>T p.R99W 17:49619291-49619291 0
33 COSM6982254 SOX9 large intestine,appendix,carcinoma,adenocarcinoma c.613A>T p.K205* 17:72122900-72122900 0
34 COSM2719086 SOX17 large intestine,appendix,carcinoma,adenocarcinoma c.329C>T p.T110M 8:54459079-54459079 0
35 COSM4596765 SMARCB1 large intestine,appendix,carcinoma,adenocarcinoma c.1130G>T p.R377L 22:23834152-23834152 0
36 COSM3724529 SMARCA4 large intestine,appendix,carcinoma,adenocarcinoma c.2438+1G>A p.? 19:11013113-11013113 0
37 COSM6983349 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1528G>T p.G510* 18:51078336-51078336 0
38 COSM14096 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1333C>T p.R445* 18:51076662-51076662 0
39 COSM14134 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1576G>T p.E526* 18:51078384-51078384 0
40 COSM14122 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1082G>A p.R361H 18:51065549-51065549 0
41 COSM6963798 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1607T>C p.L536P 18:51078415-51078415 0
42 COSM14050 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1516G>A p.V506M 18:51078324-51078324 0
43 COSM6972560 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.424+1G>T p.? 18:51048861-51048861 0
44 COSM14049 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1067C>T p.P356L 18:51065534-51065534 0
45 COSM6053946 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.413C>G p.S138* 18:51048849-51048849 0
46 COSM6976714 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1207A>T p.S403C 18:51067086-51067086 0
47 COSM14151 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1081C>A p.R361S 18:51065548-51065548 0
48 COSM6983347 SMAD3 large intestine,appendix,carcinoma,adenocarcinoma c.809G>T p.C270F 15:67181391-67181391 0
49 COSM6023609 SMAD3 large intestine,appendix,carcinoma,adenocarcinoma c.269G>T p.R90L 15:67164957-67164957 0
50 COSM3981624 SMAD3 large intestine,appendix,carcinoma,adenocarcinoma c.277C>T p.R93* 15:67164965-67164965 0
Sources

Expression for Appendix Adenocarcinoma

About this section
Search GEO for disease gene expression data for Appendix Adenocarcinoma.
Sources

Pathways for Appendix Adenocarcinoma

About this section

Pathways related to Appendix Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
10.75 ALCAM CDX2
Sources

GO Terms for Appendix Adenocarcinoma

About this section

Biological processes related to Appendix Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cornification GO:0070268 8.62 KRT20 KRT7
Sources

Sources for Appendix Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....